Cellectar Biosciences Announces Publication of Phase 1 Study of Iopofosine I 131 in Peer-Reviewed Journal Cancers

Demonstrated Favorable Safety Profile and Preliminary Clinical Activity in  Relapsed/Refractory Multiple Myeloma

Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.